| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Journal Article |
Universite Paris-Descartes, Faculte de Medecine, Institut Cochin (INSERM U567, CNRS-UMR 8104), Paris, France. valerie.bardet@cch.aphp.fr
BACKGROUND AND OBJECTIVES: Abnormal activation of several signal transduction pathways such as phosphoinositide 3-kinase (PI3K) and MAP kinases has been reported in acute myeloid leukemia (AML). To test new targeted therapeutics, it is critical to develop sensitive analytical tools to detect abnormal activation of these pathways and to monitor their inhibition in response to treatment. DESIGN AND METHODS: We analyzed Akt and ERK phosphorylation in 32 samples from patients using western blot and a two-color flow cytometry protocol using CD34. To circumvent the CD34 negative AML found in our series, we developed a two-color protocol using CD45 to isolate the blast cell population. Finally, a four-color protocol was used to detect phosphorylation in an enriched population of AML stem cells. RESULTS: We compared western blot analysis and flow cytometry for the detection of PI3K/Akt and ERK activation and found a 100% correlation between the two techniques in a series of 32 AML samples. Using a flow cytometry protocol, we were able to analyze all the patients' samples, even those with low blast infiltration or CD34 negative blast cells. We were also able to detect the phosphorylated proteins in the most immature blast cell population with the CD34+ CD38-/low CD123+ phenotype. Interpretations and CONCLUSION: Our study shows that flow cytometry is a reliable method for detecting Akt and ERK phosphorylation in all patients' samples. Activation can also be detected in the most immature blast cells, which represent exquisite target cells for new therapeutics.
This article has been cited by other articles:
|
|
 |
|
  C. Dos Santos, C. Demur, V. Bardet, N. Prade-Houdellier, B. Payrastre, and C. Recher A critical role for Lyn in acute myeloid leukemia Blood, February 15, 2008; 111(4): 2269 - 2279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tamburini, N. Chapuis, V. Bardet, S. Park, P. Sujobert, L. Willems, N. Ifrah, F. Dreyfus, P. Mayeux, C. Lacombe, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways Blood, January 1, 2008; 111(1): 379 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tamburini, C. Elie, V. Bardet, N. Chapuis, S. Park, P. Broet, P. Cornillet-Lefebvre, B. Lioure, V. Ugo, O. Blanchet, et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients Blood, August 1, 2007; 110(3): 1025 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tamburini, C. Elie, V. Bardet, S. Park, P. Broet, P. Cornillet Lefebvre, B. Lioure, N. Ifrah, F. Witz, J. Luc Harousseau, et al. Constitutive Phosphoinositide-3kinase Activation Represents a Good Prognostic Factor in De Novo AML Patients under 60 Years. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 1895 - 1895. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
